Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals

Background: Seizures are common among hospitalized patients. Levetiracetam (LEV), a synaptic vesicle protein 2A (SV2A) ligand, is a common intravenous (IV) anti-seizure medication option in hospitals. Brivaracetam (BRV), a selective SV2A ligand for treatment of focal seizures in patients ≥16 years,...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaty, Silky, Rosenthal, Ning A., Gayle, Julie, Dongre, Prashant, Ricchetti-Masterson, Kristen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667030/
https://www.ncbi.nlm.nih.gov/pubmed/34912285
http://dx.doi.org/10.3389/fneur.2021.760855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667030/
https://www.ncbi.nlm.nih.gov/pubmed/34912285
http://dx.doi.org/10.3389/fneur.2021.760855

Ejemplares similares